Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
. Mitsuhashi (Tokushima, Japan), T. Afroj (Tokushima, Japan), A. Saijo (Tokushima, Japan), K. Otsuka (Tokushima, Japan), H. Yoneda (Tokushima, Japan), K. Koyama (Tokushima, Japan), M. Sugimoto (Tokyo, Japan), O. Kondoh (Tokyo, Japan), H. Nokihara (Tokushima, Japan), Y. Nishioka (Tokushima, Japan). The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents. 1134

Member's Comments

No comment yet.

Related content which might interest you: The efficacy of immune checkpoint inhibitors in thoracic malignancies Source: Eur Respir Rev, 30 (162) 200387; 10.1183/16000617.0387-2020 Year: 2021 Histone deacetylase inhibition significantly augments human mesothelioma cellular response to chemotherapeutic agents Source: Eur Respir J 2001; 18: Suppl. 33, 396s Year: 2001 A possible role of intracellular calcium in the development of anti-cancer therapy -resistance in lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 853s Year: 2006 The clinical benefits of immune checkpoint inhibitors for thymic carcinomas Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Targeting of endothelial progenitor cells with the proteasome inhibitor bortezomib Source: Annual Congress 2009 - Highlighting the epithelial cell in lung disease: from COPD to cancer to acute lung injury Year: 2009 Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Predictive biomarker of immune checkpoint inhibitors efficacy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 The cytotoxic drug melphalan activates respiratory epithelial cells in vitro. Source: Eur Respir J 2002; 20: Suppl. 38, 282s Year: 2002 The effect of bortezomib (Velcade®) on endothelial progenitor cell functions in vitro Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 The loss of pulmonary barrier function as a result of application of anticancer agents paclitaxel, 2-methoxyestradiol, and their combination Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010 Management of pulmonary toxicity associated with immune checkpoint inhibitors Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019 Year: 2019 Role of altered immune response in CF and implication for antiinflammatory therapies Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease Year: 2012 Fast, efficient and realistic in vitro delivery of inhaled drugs to pulmonary cells: Application to the proteasome inhibitor bortezomib Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Autophagy induction by low dose cisplatin; the role of p53 in autophagy Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 Anti–fibrotic efficacy of Lck inhibitor via the suppression of TGF–ß production in regulatory T cells Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia Year: 2021 Protective effect of MAPK inhibitors and budesonide against apoptosis induced by TGF-β in primary cultures of human bronchial epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 394s Year: 2003